跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

安全信息

SML0123

Sigma-Aldrich

Deflazacort

≥98% (HPLC)

别名:

(11β,16β)-21-(acetyloxy)-11-hydroxy-2′-methyl-5′H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione, 11β,21-dihydroxy-2′-methyl-5′βH-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 2′-acetate, DL-458-IT, L-5458, azacort, oxazacort, pregna-1,4-diene-11β,21-diol-3,20-dione[17α,16α-d]-2′-methyloxazoline 21-acetate

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C25H31NO6
CAS号:
14484-47-0
分子量:
441.52
EC 号:
238-483-7
MDL编号:
MFCD00866106
UNSPSC代码:
51111800
PubChem化学物质编号:
329825173
NACRES:
NA.77

质量水平

100

方案

≥98% (HPLC)

表单

powder

颜色

white to tan

溶解性

DMSO: ≥20 mg/mL

储存温度

2-8°C

SMILES字符串

CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]23C

InChI

1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1

InChI key

FBHSPRKOSMHSIF-GRMWVWQJSA-N

基因信息

human ... NR3C1(2908)

正在寻找类似产品? 访问 产品对比指南

生化/生理作用

Deflazacort is an anti-inflammatory and immunosuppressant glucocorticoid.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

从最新的版本中选择一种：

分析证书(COA)

Lot/Batch Number
0000375408
0000366529
0000375408
0000366529
0000083330

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

David E Lebel et al.
The Journal of bone and joint surgery. American volume, 95(12), 1057-1061 (2013-06-21)
Duchenne muscular dystrophy, a progressive muscle disorder that occurs in males, causes a gradual decline in muscle strength. This progressive decline is associated with the development of scoliosis. Previous studies have shown that the use of glucocorticoids slows the progression
Eric P Hoffman et al.
Physical medicine and rehabilitation clinics of North America, 23(4), 821-828 (2012-11-10)
Although prednisone has never been formally approved for use in Duchenne muscular dystrophy (DMD) by regulatory agencies, its efficacy has been confirmed in trials dating from the 1980s. There is a strong need for optimization of both specific type of
Siliconosis: autoimmune/inflammatory syndrome induced by adjuvants (ASIA).
Mónica Caldeira et al.
The Israel Medical Association journal : IMAJ, 14(2), 137-138 (2012-06-15)
Carlo Fusco et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 16(4), 373-378 (2011-12-27)
To determine efficacy and safety of corticosteroid treatment in patients with severe Sydenham's chorea paralytic form. This is a 4 years observational study on ten patient with severe paralytic form of Sydenham's chorea unresponsive to neuroleptics and antiepileptics agents, treated
A L Mayo et al.
Neuromuscular disorders : NMD, 22(12), 1040-1045 (2012-07-25)
Quality of life in Duchenne Muscular Dystrophy (DMD) has improved significantly with corticosteroid treatment. However, corticosteroids decrease bone mass and increase vertebral fragility fracture risk. We report on bone health in 39 boys with DMD on long-term deflazacort (0.9 mg/kg/day)
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门